In vivo, the fluorescence signal in tumor-bearing brains treated with DP-CLPs–PTX–survivin siRNA was stronger than that of nonmodified CLPs–PTX–survivin siRNA, and the tumor size in the DP-CLPs–PTX–survivin siRNA-treated group was significantly reduced compared with that in the control groups, including PTX alone and nonmodified CLPs–PTX–survivin siRNA (Fig. 3A) [37]. The gene discussed is BIRC5; the disease is neoplasm.